Lucid-MS
Lucid-MS, also known as Lucid-21-302, is a protein arginine deiminase 2 (PAD2) inhibitor which is under development for the treatment of multiple sclerosis.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lucid-MS, also known as Lucid-21-302, is a protein arginine deiminase 2 (PAD2) inhibitor which is under development for the treatment of multiple sclerosis. It is taken orally. The drug is described as a non-immunomodulatory neuroprotective agent against demyelination and is said to be a potential first-in-class medication.
The pharmacokinetics of Lucid-MS have been described. It was originated by University Health Network and has been developed by FSD Pharma, Lucid Psycheceuticals, and Quantum Biopharma. As of February 2026, Lucid-MS is in phase 1 clinical trials, with at least one phase 1 trial having been completed and published.
A phase 2 trial is being planned. The chemical structure of Lucid-MS does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1345632993 under CC BY-SA 4.0; modifications have been made.